Glycogen synthase kinase‐3 inhibition overcomes epithelial‐mesenchymal transition‐associated resistance to osimertinib in EGFR‐mutant lung cancer

A novel epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor, osimertinib, has marked efficacy in patients with EGFR‐mutant lung cancer. While epithelial‐mesenchymal transition (EMT) plays a role in the resistance to various targeted drugs, its involvement in EGFR‐inhibitor resistance r...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukuda, Koji, Takeuchi, Shinji, Arai, Sachiko, Kita, Kenji, Tanimoto, Azusa, Nishiyama, Akihiro, Yano, Seiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385349/
https://www.ncbi.nlm.nih.gov/pubmed/32391602
http://dx.doi.org/10.1111/cas.14454

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385349/
https://www.ncbi.nlm.nih.gov/pubmed/32391602
http://dx.doi.org/10.1111/cas.14454

Ejemplares similares